Combination therapy with beta-adrenergic receptor antagonists and phosphodiesterase inhibitors for chronic heart failure.
Abstract Rational use of phosphodiesterase inhibitors represents an ongoing controversy in contemporary pharmacotherapy for heart failure. In randomized clinical trials, phosphodiesterase inhibitors increased cardiac output at the expense of worsening the rates of sudden cardiac death and cardiovascular mortality. Preliminary findings from ongoing clinical and preclinical investigations of phosphodiesterase activity suggest that combined use of phosphodiesterase inhibitors with beta-adrenergic antagonists may prevent these adverse outcomes. Compartmentation of cyclic adenosine 3',5'-monophosphate signaling may prove critical in determining myocardial response to combination therapy.
Van Tassell
Benjamin W
BW
Department of Pharmacotherapy, College of Pharmacy, University of Utah, Salt Lake City, UT 84112, USA. benjamin.vantassel@utah.edu
Radwanski
Przemyslaw
P
Movsesian
Matthew
M
Munger
Mark A
MA
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D002908:Chronic Disease; D000242:Cyclic AMP / Q000378:metabolism; D004359:Drug Therapy, Combination; D006333:Heart Failure / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D006801:Humans; D008954:Models, Biological; D010726:Phosphodiesterase Inhibitors / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D015398:Signal Transduction / Q000187:drug effects
D000319:Adrenergic beta-Antagonists; D010726:Phosphodiesterase Inhibitors; D000242:Cyclic AMP